Obesity treatment: novel peripheral targets
Article first published online: 7 AUG 2009
DOI: 10.1111/j.1365-2125.2009.03522.x
© 2009 The Authors. Journal compilation © 2009 The British Pharmacological Society
Additional Information
How to Cite
Field, B. C. T., Chaudhri, O. B. and Bloom, S. R. (2009), Obesity treatment: novel peripheral targets. British Journal of Clinical Pharmacology, 68: 830–843. doi: 10.1111/j.1365-2125.2009.03522.x
Publication History
- Issue published online: 27 NOV 2009
- Article first published online: 7 AUG 2009
- Received 9 July 2009 Accepted27 July 2009
- Abstract
- Article
- References
- Cited By
Keywords:
- amylin;
- cholecystokinin;
- ghrelin;
- glucagon-like peptide-1;
- obesity;
- oxyntomodulin;
- pancreatic polypeptide;
- peptide YY
Our knowledge of the complex mechanisms underlying energy homeostasis has expanded enormously in recent years. Food intake and body weight are tightly regulated by the hypothalamus, brainstem and reward circuits, on the basis both of cognitive inputs and of diverse humoral and neuronal signals of nutritional status. Several gut hormones, including cholecystokinin, glucagon-like peptide-1, peptide YY, oxyntomodulin, amylin, pancreatic polypeptide and ghrelin, have been shown to play an important role in regulating short-term food intake. These hormones therefore represent potential targets in the development of novel anti-obesity drugs. This review focuses on the role of gut hormones in short- and long-term regulation of food intake, and on the current state of development of gut hormone-based obesity therapies.

1365-2125/asset/olbannerleft.gif?v=1&s=e86b92cac3efbbd2e255b9fa97ece9623eac0b54)
1365-2125/asset/olbannerright.gif?v=1&s=6a7c47d290382bf3bc40c62461bc36a371a081bf)
